Sign in

CIK 0001699382

  • Non-accelerated filer
  • Smaller reporting company

PMV Pharmaceuticals, Inc.

Sign in to watch
Ticker
PMVP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
463218129
Phone
+1 609-642-6670
Business address
400 ALEXANDER PARK DRIVE, SUITE 301, PRINCETON, NJ, 08540
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-10-01 Eckler Matthew Joseph Director Grant or award · Stock Option (right to buy) +84,000 84,000
2026-06-04 FLOWERS KIRSTEN Director Grant or award · Stock Option (right to buy) +42,000 42,000
2026-06-04 Stelzer Laurie Director Grant or award · Stock Option (right to buy) +42,000 42,000
2026-06-04 BAUM CHARLES M Director Grant or award · Stock Option (right to buy) +42,000 42,000
2026-06-04 Gallagher Carol Giltner Director Grant or award · Stock Option (right to buy) +42,000 42,000
2026-06-04 Gallagher Carol Giltner Director Gift · Stock Option (right to buy) −42,000 0
2026-06-04 Gallagher Carol Giltner Director Gift · Stock Option (right to buy) +42,000 42,000
2026-06-04 LEVINE ARNOLD J Director Grant or award · Stock Option (right to buy) +42,000 42,000
2026-03-05 Carulli Michael Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +240,000 240,000
2026-03-05 Jalota Deepika Chief Development Officer Grant or award · Employee Stock Option (right to buy) +303,310 303,310
2026-03-05 Ticktin Robert General Counsel & COO Grant or award · Employee Stock Option (right to buy) +319,270 319,270
2026-03-05 Mack David Henry President and CEO Grant or award · Employee Stock Option (right to buy) +744,960 744,960
2025-10-27 Mack David Henry President and CEO Exercise or conversion +220,643 $1.37 $302K 451,109
2025-10-27 Mack David Henry President and CEO Exercise or conversion · Employee Stock Option (right to buy) −220,643 0
2025-10-23 ORBIMED ADVISORS LLC 10% owner Sale −1,000,000 $1.52 $1.5M 4,975,291
2025-09-10 ORBIMED ADVISORS LLC 10% owner Sale −500,000 $1.80 $900K 5,975,291
2025-07-01 Ticktin Robert General Counsel & COO Sale −23,151 $1.06 $25K 98,695
2025-07-01 Jalota Deepika Chief Development Officer Sale −33,065 $1.06 $35K 89,959
2025-07-01 Carulli Michael Chief Financial Officer Sale −28,249 $1.06 $30K 60,146
2025-07-01 Mack David Henry President and CEO Sale −58,411 $1.06 $62K 536,133

Page 1 of 23 · 457 trades